We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
Cap. Flow
+$24.2M
Cap. Flow %
3.06%
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$35.2M
2
UTHR icon
United Therapeutics
UTHR
+$14.5M
3
ABVX
Abivax
ABVX
+$9.93M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$9.38M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.02M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$10.4M
2
TERN
Terns Pharmaceuticals
TERN
+$9.58M
3
TGTX icon
TG Therapeutics
TGTX
+$8.47M
4
INCY icon
Incyte
INCY
+$7.74M
5
JNJ icon
Johnson & Johnson
JNJ
+$7.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 66.57%
2 Healthcare 33.4%
3 Consumer Discretionary 0.02%
4 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE
151
CALL
DELISTED
Apogee Therapeutics
APGE
– –
-222,500
Closed -$18.7M
AVXL icon
152
CALL
Anavex Life Sciences
AVXL
$265M
– –
-477,600
Closed -$1.47M
BBIO icon
153
BridgeBio Pharma
BBIO
$14.6B
– –
-85,311
Closed -$6.34M
CAPR icon
154
Capricor Therapeutics
CAPR
$547M
– –
-78,851
Closed -$2.39M
CELC icon
155
Celcuity
CELC
$4.68B
– –
-5,314
Closed -$613K
CMPS
156
Compass Pathways
CMPS
$1.84B
– –
-31,885
Closed -$176K
CORT icon
157
Corcept Therapeutics
CORT
$12.1B
– –
-10,000
Closed -$604K
CRSP icon
158
CALL
CRISPR Therapeutics
CRSP
$5.39B
– –
-106,300
Closed -$5.06M
CTMX icon
159
CALL
CytomX Therapeutics
CTMX
$808M
– –
-316,000
Closed -$1.49M
CYTK icon
160
CALL
Cytokinetics
CYTK
$10.1B
– –
-50,000
Closed -$3.3M
DNTH icon
161
Dianthus Therapeutics
DNTH
$6.05B
– –
-10,000
Closed -$839K
ENTA icon
162
Enanta Pharmaceuticals
ENTA
$410M
– –
-64,952
Closed -$820K
EWTX icon
163
CALL
Edgewise Therapeutics
EWTX
$4.68B
– –
-212,500
Closed -$6.69M
EYPT icon
164
EyePoint Inc
EYPT
$395M
– –
-178,545
Closed -$2.39M
GHRS icon
165
GH Research
GHRS
$1.94B
– –
-26,836
Closed -$377K
GPCR icon
166
Structure Therapeutics
GPCR
$3.38B
– –
-72,234
Closed -$3.48M
GPCR icon
167
PUT
Structure Therapeutics
GPCR
$3.38B
– –
-127,500
Closed -$6.15M
IBRX icon
168
PUT
ImmunityBio
IBRX
$8.56B
– –
-106,300
Closed -$815K
INCY icon
169
Incyte
INCY
$25.7B
– –
-78,029
Closed -$7.74M
INO icon
170
Inovio Pharmaceuticals
INO
$148M
– –
-562,665
Closed -$668K
IOVA icon
171
CALL
Iovance Biotherapeutics
IOVA
$3.98B
– –
-300,000
Closed -$1.05M
IOVA icon
172
PUT
Iovance Biotherapeutics
IOVA
$3.98B
– –
-2,900
Closed -$10.2K
JANX icon
173
CALL
Janux Therapeutics
JANX
$1.24B
– –
-31,600
Closed -$439K
JAZZ icon
174
Jazz Pharmaceuticals
JAZZ
$16B
– –
-54,755
Closed -$10.4M
KPTI icon
175
CALL
Karyopharm Therapeutics
KPTI
$40.6M
– –
-241,300
Closed -$1.34M
5 6
7
8 9

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.

By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.

  • Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
  • Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
  • Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
  • Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
  • Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
  • Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
  • Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.